{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:40:31Z","timestamp":1793745631482,"version":"4.6.1"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epigallocatechin-3-gallate (EGCG) constitutes the main component of tea polyphenols found in tea leaves and has been found to have a positive therapeutic effect on various digestive system diseases. However, no systematic review has been conducted on the research progress and mechanisms of EGCG in relation to digestive system diseases, an its toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a comprehensive literature search for preclinical studies from the inception of each database to 28th September 2025, including Embase, PubMed, Web of Science, China National Knowledge Infrastructure and Veipu Information. These studies were manually screened based on predefined criteria. A comprehensive literature review and meta-analysis were then performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 74 animal studies were initially included. Following screening, 63 studies (involving 738 animals) met the inclusion criteria for the meta-analysis. EGCG\u2019s animal experiments in digestive system diseases primarily focus on tongue squamous cancer, colorectal cancer, liver cancer, ulcerative colitis, gastric cancer, and functional gastrointestinal disorders. EGCG also has positive effects on pancreatic cancer, radiation enteritis, hepatitis B, oral cancer, esophageal cancer, radiation-induced esophagitis, hepatitis C, acute pancreatitis, fatty liver, and cancer prevention. The potential common pathways include VEGF, EGFR, Notch, Bax\/Caspase, Nrf2\/UGTIA10, JAK\/STAT, NF-\u03baB, IGF\/IGF-IR, Caspase-1, HIF-1\u03b1\/VEGF, TGF\u03b2\/p-ERK\/p-Smad1\/2 and M1\/M2 cell polarization. EGCG suppresses cell proliferation through the induction of apoptosis; however, its underlying mechanisms warrant further investigation. Administration of high-dose EGCG alone can induce hepatotoxicity, an effect that is exacerbated under inflammatory conditions. In the context of diabetes, EGCG may also lead to nephrotoxicity. It should be noted that these toxic doses substantially exceed the levels typically attained through normal dietary consumption of tea. The mechanisms responsible for EGCG-mediated toxicity remain to be fully elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:italic>In vivo<\/jats:italic>\n                      studies have indicated the potential efficacy of EGCG in managing gastrointestinal diseases. However, further investigations are necessary to validate its therapeutic benefits, elucidate the underlying mechanisms, and assess its potential toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1809860","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:28:42Z","timestamp":1781065722000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Chemoprophylaxis effect of EGCG on various digestive system diseases: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yanan","family":"Zhao","sequence":"first","affiliation":[{"name":"The First Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyu","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchao","family":"Xu","sequence":"additional","affiliation":[{"name":"Xiongan Magic Medical Laboratory","place":["Baoding, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilin","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanke","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Pang","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintong","family":"Li","sequence":"additional","affiliation":[{"name":"School of Life Sciences and Food Engineering, Hebei University of Engineering, Handan","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiao","family":"Li","sequence":"additional","affiliation":[{"name":"Xiongan Magic Medical Laboratory","place":["Baoding, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Hebei Medical University, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Song","sequence":"additional","affiliation":[{"name":"Xiongan Magic Medical Laboratory","place":["Baoding, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhe","family":"Shi","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[{"name":"Xiongan Magic Medical Laboratory","place":["Baoding, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine, Hebei University of Engineering, Handan","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Jiang","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tifs.2021.05.023","article-title":"Potential protective mechanisms of green tea polyphenol EGCG against COVID-19.","volume":"114","author":"Zhang","year":"2021","journal-title":"Trends Food Sci Technol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3390\/molecules30030654","article-title":"Epigallocatechin Gallate (EGCG): pharmacological properties, biological activities and therapeutic potential.","volume":"30","author":"Capasso","year":"2025","journal-title":"Molecules."},{"key":"B3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s43556-024-00240-9","article-title":"Epigallocatechin-3-gallate therapeutic potential in human diseases: molecular mechanisms and clinical studies.","volume":"5","author":"Alam","year":"2024","journal-title":"Mol Biomed."},{"key":"B4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2174\/1871523015666160915154443","article-title":"Anti-inflammatory action of green tea.","volume":"15","author":"Ohishi","year":"2016","journal-title":"Antiinflamm Antiallergy Agents Med Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.3390\/ijerph20064676","article-title":"Antibacterial Activity of Epigallocatechin Gallate (EGCG) against Shigella flexneri.","volume":"20","author":"Zhang","year":"2023","journal-title":"Int J Environ Res Public Health."},{"key":"B6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jcis.2024.05.080","article-title":"Multi-mechanism antitumor\/antibacterial effects of Cu-EGCG self-assembling nanocomposite in tumor nanotherapy and drug-resistant bacterial wound infections.","volume":"671","author":"Chen","year":"2024","journal-title":"J Colloid Interface Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13020-025-01124-y","article-title":"Natural anti-cancer products: insights from herbal medicine.","volume":"20","author":"Cui","year":"2025","journal-title":"Chin Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1080\/13813455.2021.1908366","article-title":"Anti-adipogenic and lipid-lowering activity of piperine and epigallocatechin gallate in 3T3-L1 adipocytes.","volume":"129","author":"Oruganti","year":"2023","journal-title":"Arch Physiol Biochem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"153316","DOI":"10.1016\/j.phymed.2020.153316","article-title":"The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer\u2019s disease animal model: a systematic review.","volume":"79","author":"Zhang","year":"2020","journal-title":"Phytomedicine."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1002\/fsn3.1121","article-title":"Chemoprevention of elite tea variety CFT-1 rich in EGCG against chemically induced liver cancer in rats.","volume":"7","author":"Liao","year":"2019","journal-title":"Food Sci Nutr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1201085","DOI":"10.3389\/fphar.2023.1201085","article-title":"The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma.","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40168-021-01115-9","article-title":"Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis.","volume":"9","author":"Wu","year":"2021","journal-title":"Microbiome."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.21873\/anticanres.17660","article-title":"The Polyphenol (-)-Epigallocatechin-3-gallate (EGCG) inhibits the proliferation of gastric cancer cells and alters microRNA signatures.","volume":"45","author":"Sasaki","year":"2025","journal-title":"Anticancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/gastro\/goaa072","article-title":"Tea polyphenol EGCG inhibited colorectal-cancer-cell proliferation and migration via downregulation of STAT3.","volume":"9","author":"Luo","year":"2021","journal-title":"Gastroenterol Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.toxrep.2020.02.008","article-title":"United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts.","volume":"7","author":"Oketch-Rabah","year":"2020","journal-title":"Toxicol Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7880","DOI":"10.1038\/s41598-018-25901-y","article-title":"Paradoxical cardiotoxicity of intraperitoneally-injected epigallocatechin gallate preparation in diabetic mice.","volume":"8","author":"Rasheed","year":"2018","journal-title":"Sci Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s12192-011-0280-8","article-title":"High-dose green tea polyphenols induce nephrotoxicity in dextran sulfate sodium-induced colitis mice by down-regulation of antioxidant enzymes and heat-shock protein expressions.","volume":"16","author":"Inoue","year":"2011","journal-title":"Cell Stress Chaperones."},{"key":"B18","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3971\/j.issn.1000-8578.2025.25.0369","article-title":"Research progress on antitumor mechanisms of EGCG.","volume":"52","author":"Wu","year":"2025","journal-title":"Cancer Res Prevent Treatment."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/foods13081232","article-title":"Comprehensive review of EGCG modification: esterification methods and their impacts on biological activities.","volume":"13","author":"Zhuang","year":"2024","journal-title":"Foods."},{"key":"B20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1631\/jzus.B2400040","article-title":"EGCG as a therapeutic agent: a systematic review of recent advances and challenges in nanocarrier strategies.","volume":"26","author":"Wong","year":"2025","journal-title":"J Zhejiang Univ Sci B."},{"key":"B21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1080\/10408398.2016.1231168","article-title":"Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): an updated review.","volume":"58","author":"Gan","year":"2018","journal-title":"Crit Rev Food Sci Nutr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2174\/0113816128319678240612114820","article-title":"Chemoprophylaxis effect of EGCG on the recurrence of colorectal cancer: a systematic review and meta-analysis.","volume":"30","author":"He","year":"2024","journal-title":"Curr Pharm Des."},{"key":"B23","doi-asserted-by":"publisher","first-page":"155408","DOI":"10.1016\/j.phymed.2024.155408","article-title":"Therapeutic effects of epigallocatechin-3-gallate for inflammatory bowel disease: a preclinical meta-analysis.","volume":"128","author":"Wei","year":"2024","journal-title":"Phytomedicine."},{"key":"B24","doi-asserted-by":"publisher","first-page":"156651","DOI":"10.1016\/j.phymed.2025.156651","article-title":"Preclinical evidence construction for epigallocatechin-3-gallate against non-alcoholic fatty liver disease: a meta-analysis and machine learning study.","volume":"142","author":"Zhang","year":"2025","journal-title":"Phytomedicine."},{"key":"B25","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.fct.2005.11.003","article-title":"Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies.","volume":"44","author":"Isbrucker","year":"2006","journal-title":"Food Chem Toxicol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.fct.2014.11.008","article-title":"Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice.","volume":"76","author":"Church","year":"2015","journal-title":"Food Chem Toxicol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.fct.2005.07.005","article-title":"Safety studies on epigallocatechin gallate (EGCG) preparations. Part 1: genotoxicity.","volume":"44","author":"Isbrucker","year":"2006","journal-title":"Food Chem Toxicol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.toxrep.2016.03.001","article-title":"Repeated dose studies with pure Epigallocatechin-3-gallate demonstrated dose and route dependant hepatotoxicity with associated dyslipidemia.","volume":"3","author":"Ramachandran","year":"2016","journal-title":"Toxicol Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jab.2014.03.001","article-title":"Possible hepatocellular toxicity of EGCG under the influence of an inflammagen.","volume":"12","author":"Saleh","year":"2014","journal-title":"J Appl Biomed."},{"key":"B30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.fct.2009.10.030","article-title":"Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice.","volume":"48","author":"Lambert","year":"2010","journal-title":"Food Chem Toxicol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.taap.2014.12.018","article-title":"Green tea polyphenol (-)-epigallocatechin-3-gallate triggered hepatotoxicity in mice: responses of major antioxidant enzymes and the Nrf2 rescue pathway.","volume":"283","author":"Wang","year":"2015","journal-title":"Toxicol Appl Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3389\/fphar.2019.01563","article-title":"Epigallocatechin-3-Gallate toxicity in children: a potential and current toxicological event in the differential diagnosis with virus-triggered fulminant hepatic failure.","volume":"10","author":"Sergi","year":"2019","journal-title":"Front Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/molecules23010038","article-title":"Dietary copper reduces the hepatotoxicity of (-)-Epigallocatechin-3-Gallate in mice.","volume":"23","author":"Kaleri","year":"2017","journal-title":"Molecules."},{"key":"B34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/s0304-3835(00)00498-5","article-title":"Dermal toxicity of topical (-)epigallocatechin-3-gallate in BALB\/c and SKH1 mice.","volume":"158","author":"Stratton","year":"2000","journal-title":"Cancer Lett."},{"key":"B35","doi-asserted-by":"publisher","first-page":"20150665","DOI":"10.1259\/bjr.20150665","article-title":"Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy.","volume":"89","author":"Zhao","year":"2016","journal-title":"Br J Radiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies.","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol."},{"key":"B38","first-page":"70","article-title":"Research on the inhibiting effect and mechanism of catechin EGCG for oral cancer cells in vitro proliferation.","volume":"39","author":"Ni","year":"2017","journal-title":"J Yichun Univ."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3971\/j.issn.1000-8578.175","article-title":"MDR-reversing Effect of (-)epigallocatechin-3-gallate on Human MDR Cell Lines KBV200.","volume":"34","author":"Gang","year":"2007","journal-title":"Cancer Res Prevent Treatment."},{"key":"B40","first-page":"530","article-title":"Effect of EGCG on proliferation and signaling pathways in oral squamous carcinoma cells.","volume":"42","author":"Liu","year":"2013","journal-title":"Acta Med Univ Sci Technol Huazhong"},{"key":"B41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.26689\/par.v8i5.8323","article-title":"Immunoregulatory effect and mechanism of Epigallocatechin-3-Gallate in a mouse oral cancer model.","volume":"8","author":"Li","year":"2024","journal-title":"Proc Anticancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"108843","DOI":"10.1016\/j.jnutbio.2021.108843","article-title":"inhibits growth of tumoral lesions on lip and tongue of K-Ras transgenic mice through the Notch pathway.","volume":"99","author":"Wei","year":"2022","journal-title":"J Nutr Biochem."},{"key":"B43","author":"Wu","year":""},{"key":"B44","author":"Zhu","year":""},{"key":"B45","first-page":"494","article-title":"Antiangiogenic effect of (-)-Epigallocatechin-3-Gallate on gastric cancer.","volume":"40","author":"Wu HongJu","year":"2011","journal-title":"J China Med Univ."},{"key":"B46","first-page":"82","article-title":"Epigallocatechin-3-gallate inhibits growth and angiogenesis of gastric cancer and its molecular mechanism.","volume":"12","author":"Zhu","year":"2009","journal-title":"Chin J Gastrointestinal Surg."},{"key":"B47","first-page":"737","article-title":"The induction of apoptosis by epigallocatechin-3-gallate in xenograft nude mice with human gastric cancer cells.","volume":"16","author":"Li","year":"2006","journal-title":"China Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3892\/etm.2012.448","article-title":"Capecitabine combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts.","volume":"3","author":"Wu","year":"2012","journal-title":"Exp Ther Med."},{"key":"B49","first-page":"425","article-title":"EGCG improves intestinal barrier in mice with unlcerative colitis by inhibiting NLRP3 inflammasome.","volume":"46","author":"Zhang","year":"2023","journal-title":"J Binzhou Med Univ."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.3892\/etm.2015.2824","article-title":"Epigallocatechin-3-gallate-induced inhibition of interleukin-6 release and adjustment of the regulatory T\/T helper 17 cell balance in the treatment of colitis in mice.","volume":"10","author":"Xu","year":"2015","journal-title":"Exp Ther Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3057268","DOI":"10.1155\/2017\/3057268","article-title":"EGCG maintains Th1\/Th2 balance and mitigates ulcerative colitis induced by dextran sulfate sodium through TLR4\/MyD88\/NF- \u03ba B signaling pathway in rats.","volume":"2017","author":"Bing","year":"2017","journal-title":"Can J Gastroenterol Hepatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"390","DOI":"10.13386\/j.issn1002-0306.2022080331","article-title":"Improving Effects of Epigallocatechin-3-gallate (EGCG) on DextranSulfate Sodium (DSS)-Induced Colitis.","volume":"44","author":"Li","year":"2023","journal-title":"Sci Technol Food Industry."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3390\/nu11081743","article-title":"Low dose epigallocatechin gallate alleviates experimental colitis by subduing inflammatory cells and cytokines, and improving intestinal permeability.","volume":"11","author":"Du","year":"2019","journal-title":"Nutrients."},{"key":"B54","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s10522-022-09976-9","article-title":"Green tea EGCG effectively alleviates experimental colitis in middle-aged male mice by attenuating multiple aspects of oxi-inflammatory stress and cell cycle deregulation.","volume":"23","author":"Diwan","year":"2022","journal-title":"Biogerontology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.biopha.2008.02.002","article-title":"Epigallocatechin-3-gallate ameliorates rats colitis induced by acetic acid.","volume":"62","author":"Ran","year":"2008","journal-title":"Biomed Pharmacother."},{"key":"B56","first-page":"12","article-title":"Protective effect and mechanism of EGCG on intestinal inflammation and intestinal barrier function in mice induced by trinitrobenzenesulfonic acid.","volume":"47","author":"Ge","year":"2022","journal-title":"J Bengbu Med College."},{"key":"B57","author":"Chen","year":""},{"key":"B58","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3390\/nu17030547","article-title":"EGCG alleviates DSS-Induced colitis by inhibiting ferroptosis through the activation of the Nrf2-GPX4 pathway and enhancing iron metabolism.","volume":"17","author":"Chen","year":"2025","journal-title":"Nutrients."},{"key":"B59","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jphs.2020.10.005","article-title":"Probing the chemoprevention potential of the antidepressant fluoxetine combined with epigallocatechin gallate or kaempferol in rats with induced early stage colon carcinogenesis.","volume":"145","author":"Hassan","year":"2021","journal-title":"J Pharmacol Sci."},{"key":"B60","first-page":"18","article-title":"Effects of epigallocatechin gallate on growth and metastases of colonic cancer.","volume":"30","author":"Yuan","year":"2010","journal-title":"Chin J Digest."},{"key":"B61","first-page":"1257","article-title":"The role of Nrf2 in the expression of UGT1A and its isoforms induced by EGCG in colon tumor.","volume":"30","author":"Yuan","year":"2010","journal-title":"Basic Clin Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1054\/bjoc.2000.1691","article-title":"EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells.","volume":"84","author":"Jung","year":"2001","journal-title":"Br J Cancer."},{"key":"B63","author":"Wang","year":""},{"key":"B64","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/s0304-3835(01)00767-4","article-title":"Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane.","volume":"177","author":"Ohishi","year":"2002","journal-title":"Cancer Lett."},{"key":"B65","doi-asserted-by":"publisher","first-page":"590","DOI":"10.2119\/2007-00050.Yuan","article-title":"Protective effects of epigallocatechin gallate on colon preneoplastic lesions induced by 2-amino-3-methylimidazo[4,5-f] quinoline in mice.","volume":"14","author":"Yuan","year":"2008","journal-title":"Mol Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/1940-6207.CAPR-08-0045","article-title":"(-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL\/KsJ-db\/db mice.","volume":"1","author":"Shimizu","year":"2008","journal-title":"Cancer Prev Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1186\/2193-1801-2-690","article-title":"(-)-Epigallocatechin-3-gallate suppresses hepatic preneoplastic lesions developed in a novel rat model of non-alcoholic steatohepatitis.","volume":"2","author":"Sumi","year":"2013","journal-title":"Springerplus."},{"key":"B68","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ejphar.2015.05.005","article-title":"Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.","volume":"761","author":"Ding","year":"2015","journal-title":"Eur J Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1111\/j.1440-1746.2007.05052.x","article-title":"Epigallocatechin gallate attenuates experimental non-alcoholic steatohepatitis induced by high fat diet.","volume":"23","author":"Kuzu","year":"2008","journal-title":"J Gastroenterol Hepatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"5599997","DOI":"10.1155\/2021\/5599997","article-title":"Epigallocatechin-3-Gallate alleviates High-Fat Diet-Induced nonalcoholic fatty liver disease via inhibition of apoptosis and promotion of autophagy through the ROS\/MAPK signaling pathway.","volume":"2021","author":"Wu","year":"2021","journal-title":"Oxid Med Cell Longev."},{"key":"B71","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3390\/nu13020599","article-title":"Epigallocatechin-3-Gallate dampens non-alcoholic fatty liver by modulating liver function, lipid profile and macrophage polarization.","volume":"13","author":"Du","year":"2021","journal-title":"Nutrients."},{"key":"B72","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3892\/ijmm_00000200","article-title":"Epigallocatechin-3-gallate improves nonalcoholic steatohepatitis model mice expressing nuclear sterol regulatory element binding protein-1c in adipose tissue.","volume":"24","author":"Ueno","year":"2009","journal-title":"Int J Mol Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"9924","DOI":"10.1039\/d0fo02152k","article-title":"Green tea polyphenol epigallocatechin-3-gallate alleviates nonalcoholic fatty liver disease and ameliorates intestinal immunity in mice fed a high-fat diet.","volume":"11","author":"Huang","year":"2020","journal-title":"Food Funct."},{"key":"B74","first-page":"510","article-title":"Therapeutic effect of epigallocatechin gallate on hyperlipidemic fatty liver in rats.","volume":"25","author":"Bin","year":"2009","journal-title":"Chin Pharmacol Bull."},{"key":"B75","author":"Song","year":""},{"key":"B76","first-page":"221","article-title":"Effects of EGCG from Tea on regulating lipid metabolism and alleviating liver injury in rats with non-alcoholic fatty liver disease.","volume":"34","author":"Yan YuJun","year":"2014","journal-title":"J Tea Sci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"18102","DOI":"10.1038\/s41598-019-54691-0","article-title":"A mouse model of subacute liver failure with ascites induced by step-wise increased doses of (-)-epigallocatechin-3-gallate.","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.3390\/app9224821","article-title":"Epigallocatechin-3-Gallate (EGCG), an active constituent of green tea: implications in the prevention of liver injury induced by diethylnitrosamine (DEN) in rats.","volume":"9","author":"Almatroodi","year":"2019","journal-title":"Appl Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e2200821","DOI":"10.1002\/mnfr.202200821","article-title":"Green Tea catechin EGCG ameliorates thioacetamide-induced hepatic encephalopathy in rats via modulation of the microbiota-gut-liver axis.","volume":"67","author":"Zhou","year":"2023","journal-title":"Mol Nutr Food Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.7603\/s40681-015-0015-8","article-title":"Protective effects of (-)-epigallocatechin-3-gallate against acetaminophen-induced liver injury in rats).","volume":"5","author":"Yao","year":"2015","journal-title":"Biomedicine."},{"key":"B81","first-page":"322","article-title":"Epigallocatechin gallate inhibits hepatocyte apoptosis and improves liver function in rats with biliary obstruction through the PI3K\/AKT signaling pathway.","volume":"42","author":"Jiang","year":"2020","journal-title":"Anat Res."},{"key":"B82","author":"Zhou","year":""},{"key":"B83","author":"Zhou","year":""},{"key":"B84","author":"Zhao","year":""},{"key":"B85","author":"Xiao","year":""},{"key":"B86","first-page":"1245","article-title":"Effect of green tea extractive, EGCG, on ultrastructure of HepG2 transplanted tumor in nude mice.","volume":"24","author":"Qin","year":"2012","journal-title":"Med J West China"},{"key":"B87","first-page":"877","article-title":"The effect of green tea extractive epigallocatechin gallate on the angiogenesis of HepG2 transplanted tumor in nude mice.","volume":"27","author":"Qin","year":"2012","journal-title":"West China Med J."},{"key":"B88","first-page":"216","article-title":"Inhibition of paclitaxel combined with epigallo catechin gallate on hepatoma carcinoma cell multiplication and tumor growth in bearing cancer nude mice.","volume":"32","author":"Guo","year":"2015","journal-title":"J Xinxiang Med Univ."},{"key":"B89","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cbi.2009.07.015","article-title":"(-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R.","volume":"182","author":"Yasuda","year":"2009","journal-title":"Chem Biol Interact."},{"key":"B90","doi-asserted-by":"publisher","first-page":"113111","DOI":"10.1016\/j.biopha.2022.113111","article-title":"Epigallocatechin-3-gallate inhibits osteopontin expression and prevents experimentally induced hepatic fibrosis.","volume":"151","author":"George","year":"2022","journal-title":"Biomed Pharmacother."},{"key":"B91","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jnutbio.2006.12.016","article-title":"Green tea polyphenol epigallocatechin-3-gallate inhibits oxidative damage and preventive effects on carbon tetrachloride-induced hepatic fibrosis.","volume":"18","author":"Zhen","year":"2007","journal-title":"J Nutr Biochem."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1147379","DOI":"10.3389\/fimmu.2023.1147379","article-title":"Inhibition of macrophages inflammasome activation via autophagic degradation of HMGB1 by EGCG ameliorates HBV-induced liver injury and fibrosis.","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2147\/DDDT.S99420","article-title":"Epigallocatechin-3-gallate attenuates apoptosis and autophagy in concanavalin A-induced hepatitis by inhibiting BNIP3.","volume":"10","author":"Li","year":"2016","journal-title":"Drug Des Devel Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.12449\/JCH250716","article-title":"Efficacy and mechanism of epigallocatechin-3-gallate in treatment of experimental metabolic dysfunction-associated steatohepatitis.","volume":"41","author":"Xu","year":"2025","journal-title":"J Clin Hepatol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"305","DOI":"10.11847\/zgggws2014-30-03-16","article-title":"Effects of epigallocatechin-3-gallate on expression of hepcidin mRNA in liver of mice with alcoholic liver disease.","volume":"30","author":"Wei","year":"2014","journal-title":"Chin J Public Health."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jsps.2022.06.021","article-title":"Epigallocatechin gallate ameliorates tetrahydrochloride-induced liver toxicity in rats via inhibition of TGF\u03b2 \/ p-ERK\/p-Smad1\/2 signaling, antioxidant, anti-inflammatory activity.","volume":"30","author":"Mostafa-Hedeab","year":"2022","journal-title":"Saudi Pharm J."},{"key":"B97","first-page":"425","article-title":"Effect of epigallocatechin -3- gallate on the crulein -induced acute pancreatitisassociated lung injury in mice.","volume":"34","author":"Tuo","year":"2018","journal-title":"Chin J Clin Pharmacol."},{"key":"B98","first-page":"4061","article-title":"The effect of epigallocatechin-3-gallate EGCG on mice with acute pancreatitis.","volume":"28","author":"Yang","year":"2012","journal-title":"J Pract Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1349-7006.1989.tb01666.x","article-title":"Inhibitory effect of (-)-epigallocatechin gallate on carcinogenesis with N-ethyl-N\u2019-nitro-N-nitrosoguanidine in mouse duodenum.","volume":"80","author":"Fujita","year":"1989","journal-title":"Jpn J Cancer Res."},{"key":"B100","first-page":"255","article-title":"EGCG promotes the production of colorectal adenoma induced by AOM\/DSS in mice.","volume":"48","author":"Liu","year":"2019","journal-title":"J China Med Univ."},{"key":"B101","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1111\/cas.15142","article-title":"Gut-liver axis-mediated mechanism of liver cancer: a special focus on the role of gut microbiota.","volume":"112","author":"Ohtani","year":"2021","journal-title":"Cancer Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.3390\/cancers15123143","article-title":"The role of microbiota in pancreatic cancer.","volume":"15","author":"Papa","year":"2023","journal-title":"Cancers."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/s41467-019-09964-7","article-title":"Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders.","volume":"10","author":"Saffouri","year":"2019","journal-title":"Nat Commun."},{"key":"B104","doi-asserted-by":"publisher","first-page":"345","DOI":"10.23736\/S1121-421X.17.02380-7","article-title":"Gut microbiota and gastric disease.","volume":"63","author":"Sgambato","year":"2017","journal-title":"Minerva Gastroenterol Dietol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1080\/19490976.2020.1762520","article-title":"The role of gastric microbiota in gastric cancer.","volume":"11","author":"Stewart","year":"2020","journal-title":"Gut Microbes."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1809860\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:28:54Z","timestamp":1781065734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1809860\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":105,"alternative-id":["10.3389\/fmed.2026.1809860"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1809860","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1809860"}}